Publicacións (39) Publicacións de Sergio Vázquez Estévez

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

    The Lancet, Vol. 401, Núm. 10379, pp. 821-832

  3. Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

    Targeted Oncology, Vol. 18, Núm. 5, pp. 639-641

2022

  1. Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

    Cancers, Vol. 14, Núm. 4

  2. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

  3. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

    Oral Oncology, Vol. 134

2021

  1. Blood-based protein biomarkers in bladder urothelial tumors

    Journal of Proteomics, Vol. 247

  2. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial

    Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56

  3. Detection of circulating serum protein biomarkers of non-muscle invasive bladder cancer after protein corona-silver nanoparticles analysis by swath-ms

    Nanomaterials, Vol. 11, Núm. 9

  4. Proteomics as a complementary technique to characterize bladder cancer

    Cancers, Vol. 13, Núm. 21

2020

  1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579

  2. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

    Lung Cancer, Vol. 150, pp. 62-69

  3. Identification of a profile of neutrophil-derived granule proteins in the surface of gold nanoparticles after their interaction with human breast cancer sera

    Nanomaterials, Vol. 10, Núm. 6, pp. 1-18

  4. Potential clinical applications of the personalized, disease-specific protein corona on nanoparticles

    Clinica Chimica Acta, Vol. 501, pp. 102-111

  5. Proteomic investigation on bio-corona of Au, Ag and Fe nanoparticles for the discovery of triple negative breast cancer serum protein biomarkers

    Journal of Proteomics, Vol. 212

2019

  1. Proteomic analysis of the bio-corona formed on the surface of (Au, Ag, Pt)-nanoparticles in human serum

    Colloids and Surfaces B: Biointerfaces, Vol. 177, pp. 141-148

2018

  1. Abordaje del paciente con cáncer renal: ¿existe la colaboración entre urología y oncología?

    Actas Urologicas Espanolas

  2. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group

    Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1467-1473

  3. Novel functionalized nanomaterials for the effective enrichment of proteins and peptides with post-translational modifications

    Journal of Proteomics, Vol. 181, pp. 170-189

2017

  1. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9